Vestmark Advisory Solutions Inc. bought a new stake in shares of Beam Therapeutics Inc. (NASDAQ:BEAM – Free Report) in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm bought 98,215 shares of the company’s stock, valued at approximately $2,673,000. Vestmark Advisory Solutions Inc. owned about 0.12% of Beam Therapeutics at the end of the most recent reporting period.
Other hedge funds also recently made changes to their positions in the company. Allworth Financial LP increased its holdings in Beam Therapeutics by 163.7% in the 3rd quarter. Allworth Financial LP now owns 1,105 shares of the company’s stock worth $27,000 after acquiring an additional 686 shares during the last quarter. First Horizon Advisors Inc. raised its position in shares of Beam Therapeutics by 125.9% in the fourth quarter. First Horizon Advisors Inc. now owns 994 shares of the company’s stock valued at $27,000 after purchasing an additional 554 shares during the period. China Universal Asset Management Co. Ltd. lifted its stake in shares of Beam Therapeutics by 84.0% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 2,272 shares of the company’s stock valued at $55,000 after buying an additional 1,037 shares in the last quarter. Signaturefd LLC lifted its stake in shares of Beam Therapeutics by 4,605.3% during the 3rd quarter. Signaturefd LLC now owns 2,682 shares of the company’s stock valued at $65,000 after buying an additional 2,625 shares in the last quarter. Finally, Nisa Investment Advisors LLC boosted its holdings in shares of Beam Therapeutics by 70.0% in the third quarter. Nisa Investment Advisors LLC now owns 3,312 shares of the company’s stock worth $80,000 after acquiring an additional 1,364 shares during the period. 99.68% of the stock is currently owned by institutional investors.
Insider Activity at Beam Therapeutics
In other news, insider Fmr Llc sold 1,565 shares of the firm’s stock in a transaction that occurred on Tuesday, February 13th. The shares were sold at an average price of $30.76, for a total value of $48,139.40. Following the transaction, the insider now owns 2,771,913 shares in the company, valued at $85,264,043.88. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. In related news, CEO John M. Evans sold 60,000 shares of the business’s stock in a transaction dated Thursday, March 28th. The stock was sold at an average price of $33.86, for a total transaction of $2,031,600.00. Following the transaction, the chief executive officer now owns 998,262 shares in the company, valued at approximately $33,801,151.32. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, insider Fmr Llc sold 1,565 shares of the stock in a transaction that occurred on Tuesday, February 13th. The stock was sold at an average price of $30.76, for a total value of $48,139.40. Following the completion of the sale, the insider now owns 2,771,913 shares of the company’s stock, valued at approximately $85,264,043.88. The disclosure for this sale can be found here. Insiders sold 96,804 shares of company stock worth $3,211,869 in the last ninety days. 4.20% of the stock is owned by company insiders.
Analyst Ratings Changes
View Our Latest Stock Report on BEAM
Beam Therapeutics Price Performance
Shares of Beam Therapeutics stock traded up $0.41 during trading on Friday, reaching $23.13. The company’s stock had a trading volume of 1,226,247 shares, compared to its average volume of 1,664,112. The firm’s 50-day moving average is $30.98 and its two-hundred day moving average is $28.08. Beam Therapeutics Inc. has a 52-week low of $16.95 and a 52-week high of $49.50.
Beam Therapeutics (NASDAQ:BEAM – Get Free Report) last posted its quarterly earnings results on Tuesday, February 27th. The company reported $1.73 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.69) by $2.42. The business had revenue of $316.20 million during the quarter, compared to analyst estimates of $34.16 million. Beam Therapeutics had a negative net margin of 35.09% and a negative return on equity of 15.90%. The company’s revenue was up 1481.0% on a year-over-year basis. During the same period in the prior year, the business posted ($0.54) earnings per share. Equities research analysts expect that Beam Therapeutics Inc. will post -5.53 EPS for the current year.
Beam Therapeutics Company Profile
Beam Therapeutics Inc, a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States. It develops BEAM-101 for the treatment of sickle cell disease or beta-thalassemia; and BEAM-302, a liver-targeting LNP formulation to treat severe alpha-1 antitrypsin deficiency; BEAM-201, an anti-CD7 CAR-T product candidate, which is in Phase 1/2 clinical trials for the treatment of refractory T-cell acute lymphoblastic leukemia/T cell lymphoblastic lymphoma; and BEAM-301, a liver-targeting LNP formulation for the treatment of glycogen storage disease 1a.
Featured Stories
- Five stocks we like better than Beam Therapeutics
- What does consumer price index measure?
- MarketBeat Week in Review – 4/29 – 5/3
- What is a buyback in stocks? A comprehensive guide for investors
- Apple’s Earnings Show Investors Its Strength and Its Weakness
- Dividend King Proctor & Gamble Is A Buy On Post-Earnings Weakness
- Bargain Alert: 3 Large Caps With Extremely Oversold RSIs
Receive News & Ratings for Beam Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Beam Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.